These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 12233260)

  • 1. [Monoamine oxidase inhibitors: prospects for the use in clinical practice].
    Evtushenko SK; Lutskiĭ IS; Efimenko VN; Kazarian NE
    Zh Nevrol Psikhiatr Im S S Korsakova; 2002; 102(8):53-60. PubMed ID: 12233260
    [No Abstract]   [Full Text] [Related]  

  • 2. MAO-B inhibitors for the treatment of Parkinson's disease.
    Mov Disord; 2002; 17 Suppl 4():S38-44. PubMed ID: 12211138
    [No Abstract]   [Full Text] [Related]  

  • 3. MAO inhibitors.
    Keller D
    Cleve Clin J Med; 2011 Feb; 78(2):81; author reply 81. PubMed ID: 21365960
    [No Abstract]   [Full Text] [Related]  

  • 4. Monoamine oxidase inhibitors and their pharmacological significance.
    Sandler M
    Acta Neurol Scand Suppl; 1983; 95():37-41. PubMed ID: 6428147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selegiline's neuroprotective capacity revisited.
    Riederer P; Lachenmayer L
    J Neural Transm (Vienna); 2003 Nov; 110(11):1273-8. PubMed ID: 14628191
    [No Abstract]   [Full Text] [Related]  

  • 6. MAO-B inhibitor know-how: back to the pharm.
    Lewitt PA
    Neurology; 2009 Apr; 72(15):1352-7. PubMed ID: 19365057
    [No Abstract]   [Full Text] [Related]  

  • 7. Possible mechanisms of action of (-)deprenyl and other MAO-B inhibitors in some neurologic and psychiatric disorders.
    Berry MD; Juorio AV; Paterson IA
    Prog Neurobiol; 1994 Oct; 44(2):141-61. PubMed ID: 7831475
    [No Abstract]   [Full Text] [Related]  

  • 8. Monoamine oxidase inhibitors, cognitive functions and neurodegenerative diseases.
    Delumeau JC; Bentué-Ferrer D; Gandon JM; Amrein R; Belliard S; Allain H
    J Neural Transm Suppl; 1994; 41():259-66. PubMed ID: 7931235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A perspective on adjunctive therapy for Parkinson disease with monoamine oxidase-B inhibition.
    LeWitt PA
    Clin Neuropharmacol; 2007; 30(5):305-7. PubMed ID: 17909310
    [No Abstract]   [Full Text] [Related]  

  • 10. A new low-dose formulation of selegiline: clinical efficacy, patient preference and selectivity for MAO-B inhibition.
    Clarke A; Johnson ES; Mallard N; Corn TH; Johnston A; Boyce M; Warrington S; MacMahon DG
    J Neural Transm (Vienna); 2003 Nov; 110(11):1257-71. PubMed ID: 14628190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MAO-B inhibitors in Parkinson's disease.
    Olanow CW
    Adv Neurol; 1993; 60():666-71. PubMed ID: 8420207
    [No Abstract]   [Full Text] [Related]  

  • 12. Rasagiline.
    Schapira A; Bate G; Kirkpatrick P
    Nat Rev Drug Discov; 2005 Aug; 4(8):625-6. PubMed ID: 16106586
    [No Abstract]   [Full Text] [Related]  

  • 13. MAO type B inhibitors as adjunct to L-dopa therapy.
    Youdim MB; Finberg JP
    Adv Neurol; 1987; 45():127-36. PubMed ID: 3103383
    [No Abstract]   [Full Text] [Related]  

  • 14. A review of the mechanisms and role of monoamine oxidase inhibitors in Parkinson's disease.
    Youdim MB; Riederer PF
    Neurology; 2004 Oct; 63(7 Suppl 2):S32-5. PubMed ID: 15477584
    [No Abstract]   [Full Text] [Related]  

  • 15. Neuroprotection for Parkinson's disease: prospects and promises.
    Olanow CW; Schapira AH; Agid Y
    Ann Neurol; 2003; 53 Suppl 3():S1-2. PubMed ID: 12666093
    [No Abstract]   [Full Text] [Related]  

  • 16. Neuroprotection by selegiline and other MAO inhibitors.
    Stern G
    J Neural Transm Suppl; 1998; 52():99-107. PubMed ID: 9564613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selegiline HC1: Selective MAO-type B inhibitor.
    Koller WC; Giron LT
    Neurology; 1990 Oct; 40(10 Suppl 3):suppl 58-60. PubMed ID: 2120616
    [No Abstract]   [Full Text] [Related]  

  • 18. Catecholamine metabolism. From molecular understanding to clinical diagnosis and treatment. Overview.
    Boulton AA; Eisenhofer G
    Adv Pharmacol; 1998; 42():273-92. PubMed ID: 9327897
    [No Abstract]   [Full Text] [Related]  

  • 19. Selegiline for Parkinson's disease.
    Calesnick B
    Am Fam Physician; 1990 Feb; 41(2):589-91. PubMed ID: 2105624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transdermal selegiline (Emsam).
    Med Lett Drugs Ther; 2006 May; 48(1235):41-2. PubMed ID: 16770292
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.